Want to see ATAI full AI Analyst Report?

Atai Beckley N.V. (ATAI) Stock Forecast & Price Target

2,212 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ATAI Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Atai

Beckley N.V.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ATAI Stock 12 Month Forecast

Average Price Target

$16.71

▲(314.75% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Atai Beckley N.V. in the last 3 months. The average price target is $16.71 with a high forecast of $25.00 and a low forecast of $14.00. The average price target represents a 314.75% change from the last price of $4.03.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","7.25":"$7.25","13.5":"$13.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.714285714285715,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.82,6.372307692307693,7.924615384615385,9.476923076923077,11.02923076923077,12.581538461538463,14.133846153846154,15.686153846153847,17.23846153846154,18.790769230769232,20.343076923076925,21.895384615384618,23.447692307692307,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.82,5.734945054945055,6.64989010989011,7.564835164835165,8.47978021978022,9.394725274725275,10.309670329670329,11.224615384615385,12.13956043956044,13.054505494505495,13.96945054945055,14.884395604395605,15.79934065934066,{"y":16.714285714285715,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.82,5.526153846153846,6.2323076923076925,6.938461538461539,7.644615384615385,8.350769230769231,9.056923076923077,9.763076923076923,10.46923076923077,11.175384615384615,11.881538461538462,12.587692307692308,13.293846153846154,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.17,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.59,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.09,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.82,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$16.71

Lowest Price Target$14.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$25

Buy

520.35%

Upside

Reiterated

06/25/26

Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (NASDAQ: ATAI), Madrigal Pharmaceuticals (NASDAQ: MDGL) and Verastem (NASDAQ: VSTM)

Justin Walsh

JonesTrading

$16

Buy

297.02%

Upside

Reiterated

06/25/26

Analysts Offer Insights on Healthcare Companies: Zenas BioPharma, Inc. (NASDAQ: ZBIO) and Atai Beckley N.V. (NASDAQ: ATAI)

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

05/13/26

Clear FDA Path and Phase 3 Advancement of BPL003 Underpin Buy Rating on atai, With Strong Cash Runway Through 2029

Ami Fadia

Needham

$15

Buy

272.21%

Upside

Assigned

05/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Sumant Kulkarni

Canaccord Genuity

$15

Buy

272.21%

Upside

Reiterated

05/13/26

Canaccord Genuity Sticks to Their Buy Rating for Atai Beckley N.V. (ATAI)

Harry Gillis

Berenberg Bank

$13→$14

Buy

247.39%

Upside

Reiterated

04/20/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Eddie Hickman

Guggenheim

$11→$16

Buy

297.02%

Upside

Reiterated

04/16/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Atai Beckley N.V. (NASDAQ: ATAI)

Jay Olson

Oppenheimer

$14→$16

Buy

297.02%

Upside

Assigned

04/05/26

Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), MapLight Therapeutics, Inc. (MPLT)

David Hoang

Deutsche Bank

$12

Buy

197.77%

Upside

Initiated

03/26/26

AtaiBeckley initiated with a Buy at Deutsche BankAtaiBeckley initiated with a Buy at Deutsche Bank

Michael Okunewitch

Maxim Group

$10

Buy

148.14%

Upside

Assigned

03/17/26

AtaiBeckley: Advancing BPL-003 Into Pivotal Phase 3 With Strategic Optionality and Strong Cash Runway Supporting a Buy Rating

Andrew Tsai

Jefferies

$10

Buy

148.14%

Upside

Reiterated

03/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Nathan Weinstein

Aegis Capital

Buy

98.51%

Upside

Reiterated

07/02/25

Aegis Capital Remains a Buy on ATAI Life Sciences (ATAI)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$25

Buy

520.35%

Upside

Reiterated

06/25/26

Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (NASDAQ: ATAI), Madrigal Pharmaceuticals (NASDAQ: MDGL) and Verastem (NASDAQ: VSTM)

Justin Walsh

JonesTrading

$16

Buy

297.02%

Upside

Reiterated

06/25/26

Analysts Offer Insights on Healthcare Companies: Zenas BioPharma, Inc. (NASDAQ: ZBIO) and Atai Beckley N.V. (NASDAQ: ATAI)

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

05/13/26

Clear FDA Path and Phase 3 Advancement of BPL003 Underpin Buy Rating on atai, With Strong Cash Runway Through 2029

Ami Fadia

Needham

$15

Buy

272.21%

Upside

Assigned

05/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Sumant Kulkarni

Canaccord Genuity

$15

Buy

272.21%

Upside

Reiterated

05/13/26

Canaccord Genuity Sticks to Their Buy Rating for Atai Beckley N.V. (ATAI)

Harry Gillis

Berenberg Bank

$13→$14

Buy

247.39%

Upside

Reiterated

04/20/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Eddie Hickman

Guggenheim

$11→$16

Buy

297.02%

Upside

Reiterated

04/16/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Atai Beckley N.V. (NASDAQ: ATAI)

Jay Olson

Oppenheimer

$14→$16

Buy

297.02%

Upside

Assigned

04/05/26

Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), MapLight Therapeutics, Inc. (MPLT)

David Hoang

Deutsche Bank

$12

Buy

197.77%

Upside

Initiated

03/26/26

AtaiBeckley initiated with a Buy at Deutsche BankAtaiBeckley initiated with a Buy at Deutsche Bank

Michael Okunewitch

Maxim Group

$10

Buy

148.14%

Upside

Assigned

03/17/26

AtaiBeckley: Advancing BPL-003 Into Pivotal Phase 3 With Strategic Optionality and Strong Cash Runway Supporting a Buy Rating

Andrew Tsai

Jefferies

$10

Buy

148.14%

Upside

Reiterated

03/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Nathan Weinstein

Aegis Capital

Buy

98.51%

Upside

Reiterated

07/02/25

Aegis Capital Remains a Buy on ATAI Life Sciences (ATAI)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Atai Beckley N.V.

3 Months

Michael OkunewitchMaxim Group

Success Rate

10/13 ratings generated profit

Average Return

+28.16%

Copying Michael Okunewitch's trades and holding each position for 3 Months would result in 76.92% of your transactions generating a profit, with an average return of +28.16% per trade.

1 Year

Michael OkunewitchMaxim Group

Success Rate

10/13 ratings generated profit

Average Return

+54.33%

Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +54.33% per trade.

2 Years

Michael OkunewitchMaxim Group

Success Rate

11/13 ratings generated profit

Average Return

+66.13%

Copying Michael Okunewitch's trades and holding each position for 2 Years would result in 84.62% of your transactions generating a profit, with an average return of +66.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ATAI Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ATAI has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ATAI average Analyst price target in the past 3 months is 16.71.

Each month's total comprises the sum of three months' worth of ratings.

ATAI Financial Forecast

ATAI Earnings Forecast

Next quarter’s earnings estimate for ATAI is -$0.11 with a range of -$0.21 to -$0.08. The previous quarter’s EPS was -$0.08. ATAI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ATAI has Performed in-line its overall industry.

ATAI Sales Forecast

Next quarter’s sales forecast for ATAI is $111.00K with a range of $0.00 to $900.00K. The previous quarter’s sales results were $954.00K. ATAI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ATAI has Performed in-line its overall industry.

ATAI Stock Forecast FAQ

What is ATAI’s average 12-month price target, according to analysts?

Based on analyst ratings, Atai Beckley N.V.’s 12-month average price target is 16.71.

What is ATAI’s upside potential, based on the analysts’ average price target?

Atai Beckley N.V. has 314.75% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ATAI a Buy, Sell or Hold?

Atai Beckley N.V. has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Atai Beckley N.V.’s price target?

The average price target for Atai Beckley N.V. is 16.71. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $14.00. The average price target represents 314.75% Increase from the current price of $4.03.

What do analysts say about Atai Beckley N.V.?

Atai Beckley N.V.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of ATAI?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Atai Beckley N.V. (ATAI) Stock Forecast & Price Target

ATAI Analyst Ratings

ATAI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Atai Beckley N.V.

ATAI Analyst Recommendation Trends

ATAI Financial Forecast

ATAI Earnings Forecast

ATAI Sales Forecast

ATAI Stock Forecast FAQ

Detailed List of Analyst Forecasts